Alice P Chen

List of Publications by Year
in descending order

248 papers	12,095 citations	36303 51 h-index	30087 103 g-index
251 all docs	251 docs citations	251 times ranked	17890 citing authors

#	Article	IF	Citations
1	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncology, The, 2017, 18, e143-e152.	10.7	1,612
2	RECIST 1.1â€"Update and clarification: From the RECIST committee. European Journal of Cancer, 2016, 62, 132-137.	2.8	1,143
3	Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Journal of the National Cancer Institute, 2014, 106, dju244-dju244.	6.3	689
4	Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies. Journal of Clinical Oncology, 2009, 27, 2705-2711.	1.6	303
5	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2386-2394.	1.6	276
6	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. Journal of Clinical Oncology, 2020, 38, 1378-1388.	1.6	265
7	Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2015, 33, 3409-3415.	1.6	261
8	Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0. Journal of the American Academy of Dermatology, 2012, 67, 1025-1039.	1.2	244
9	Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas. Cancer Research, 2011, 71, 5626-5634.	0.9	228
10	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation â€" An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2015, 137, 386-391.	1.4	224
11	RECIST 1.1 â€“ Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. European Journal of Cancer, 2016, 62, 138-145.	2.8	211
12	Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2011, 29, 2689-2695.	1.6	204
13	A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas. Clinical Cancer Research, 2012, 18, 1726-1734.	7.0	186
14	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of Clinical Oncology, 2020, 38, 3883-3894.	1.6	168
15	Clinical Activity of the Î³-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	145
16	Dabrafenib and Trametinib in Patients With Tumors With BRAF^{V600E} Mutations: Results of the NCI-MATCH Trial Subprotocol H. Journal of Clinical Oncology, 2020, 38, 3895-3904.	1.6	145
17	A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Supportive Care in Cancer, 2010, 18, 509-522.	2.2	142
18	National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 71-76.	3.8	141

#	Article	IF	Citations
19	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. Journal of the National Cancer Institute, 2020, 112, 1021-1029.	6.3	138
20	PARP Inhibitor Treatment in Ovarian and Breast Cancer. Current Problems in Cancer, 2011, 35, 7-50.	2.0	132
21	Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1Î±), in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 73, 343-348.	2.3	129
22	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. European Journal of Cancer, 2018, 89, 19-26.	2.8	125
23	Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clinical Cancer Research, 2015, 21, 1574-1582.	7.0	124
24	Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies. Clinical Cancer Research, 2007, 13, 5411-5417.	7.0	122
25	Advances in using PARP inhibitors to treat cancer. BMC Medicine, 2012, 10, 25.	5.5	120
26	Cognitive interviewing of the US National Cancer Instituteâ€™s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Quality of Life Research, 2014, 23, 257-269.	3.1	117
27	PARP inhibitors: its role in treatment of cancer. Chinese Journal of Cancer, 2011, 30, 463-471.	4.9	110
28	Nivolumab Is Effective in Mismatch Repairâ€“Deficient Noncolorectal Cancers: Results From Arm Z1Dâ€”A Subprotocol of the NCI-MATCH (EAY131) Study. Journal of Clinical Oncology, 2020, 38, 214-222.	1.6	106
29	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. Journal of Clinical Oncology, 2020, 38, 2407-2417.	1.6	102
30	Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Annals of Oncology, 2019, 30, 1821-1830.	1.2	99
31	Designing Phase 0 Cancer Clinical Trials. Clinical Cancer Research, 2008, 14, 3675-3682.	7.0	95
32	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wildâ€type BRCA pancreatic ductal adenocarcinoma. Cancer, 2018, 124, 1374-1382.	4.1	91
33	Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells. Seminars in Oncology, 2016, 43, 464-475.	2.2	89
34	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clinical Cancer Research, 2017, 23, 4066-4076.	7.0	87
35	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2016, 22, 3227-3237.	7.0	85
36	Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2007, 7, 325-334.	3.4	83

#	Article	IF	Citations
37	Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research, 2012, 18, 6023-6031.	7.0	81
38	Randomized Comparison of 3 High-Level Disinfection and Sterilization Procedures for Duodenoscopes. Gastroenterology, 2017, 153, 1018-1025.	1.3	80
39	Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin. Clinical Cancer Research, 2011, 17, 6574-6581.	7.0	77
40	Molecular Pathways: Targeting PARP in Cancer Treatment. Clinical Cancer Research, 2013, 19, 977-984.	7.0	76
41	Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Current Problems in Cancer, 2017, 41, 182-193.	2.0	75
42	Poly (<scp>ADP</scp>) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Medicine, 2014, 3, 1579-1594.	2.8	74
43	The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunology, Immunotherapy, 2000, 49, 517-529.	4.2	73
44	Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Investigational New Drugs, 2012, 30, 749-757.	2.6	72
45	Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay. PLoS ONE, 2017, 12, e0171582.	2.5	72
46	Clinical Evolution of Epithelialâ€“Mesenchymal Transition in Human Carcinomas. Cancer Research, 2020, 80, 304-318.	0.9	71
47	A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis. Clinical Cancer Research, 2015, 21, 68-76.	7.0	65
48	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell, 2021, 39, 38-53.e7.	16.8	65
49	A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium reportâ€. Neuro-Oncology, 2014, 16, 1661-1668.	1.2	60
50	Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. Clinical Cancer Research, 2011, 17, 4872-4881.	7.0	59
51	Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs, 2016, 34, 355-363.	2.6	58
52	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. Clinical Cancer Research, 2017, 23, 697-706.	7.0	56
53	RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. Journal of Clinical Oncology, 2019, 37, 1102-1110.	1.6	53
54	An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Chinese Clinical Oncology, 2015, 4, 31.	1.2	53

#	Article	IF	Citations
55	Phase I and Pharmacologic Study of Irinotecan Administered as a 96-Hour Infusion Weekly to Adult Cancer Patients. Journal of Clinical Oncology, 2000, 18, 659-659.	1.6	52
56	Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers. Journal of the National Cancer Institute, 2015, 107, djv003-djv003.	6.3	52
57	New treatment option for ovarian cancer: PARP inhibitors. Gynecologic Oncology Research and Practice, 2016, 3, 3.	3.6	50
58	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Investigational New Drugs, 2011, 29, 1432-1440.	2.6	49
59	Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 3794-3802.	7.0	49
60	Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor. JAMA Oncology, 2021, 7, 271.	7.1	49
61	Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).. Journal of Clinical Oncology, 2014, 32, 2570-2570.	1.6	49
62	Increased plasma homocysteine and S-adenosylhomocysteine and decreased methionine is associated with altered phosphatidylcholine and phosphatidylethanolamine in cystic fibrosis. Journal of Pediatrics, 2003, 143, 351-356.	1.8	47
63	A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. Gynecologic Oncology, 2017, 144, 486-490.	1.4	47
64	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clinical Cancer Research, 2020, 26, 1812-1819.	7.0	47
65	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget, 2017, 8, 32918-32929.	1.8	46
66	Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemotherapy and Pharmacology, 1995, 36, 513-523.	2.3	44
67	Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 921-930.	2.6	44
68	PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs, 2017, 77, 113-130.	10.9	44
69	A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. Clinical Cancer Research, 2018, 24, 744-752.	7.0	43
70	Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. Journal of Molecular Diagnostics, 2016, 18, 51-67.	2.8	42
71	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2021, 27, 2989-2995.	7.0	42
72	Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. Frontiers in Oncology, 2019, 9, 53.	2.8	39

#	Article	IF	Citations
73	A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, 1015-1015.	1.6	38
74	Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle, 2011, 10, 4074-4082.	2.6	37
75	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clinical Cancer Research, 2017, 23, 899-907.	7.0	37
76	Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3834-3844.	7.0	36
77	Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).. Journal of Clinical Oncology, 2021, 39, 11519-11519.	1.6	36
78	Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023). Sarcoma, 2020, 2020, 1-8.	1.3	33
79	Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 78, 73-81.	2.3	32
80	First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile. Investigational New Drugs, 2018, 36, 230-239.	2.6	32
81	What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?. Journal of Oncology Practice, 2018, 14, e722-e728.	2.5	31
82	Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2019, 84, 1289-1301.	2.3	29
83	Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors.. Journal of Clinical Oncology, 2018, 36, 101-101.	1.6	29
84	Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. Journal of Clinical Oncology, 2022, 40, 1552-1561.	1.6	26
85	Poly(Adenosine Diphosphateâ€“Ribose) Polymerase Inhibitors in Cancer Treatment. Hematology/Oncology Clinics of North America, 2012, 26, 649-670.	2.2	24
86	Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 69, 431-438.	2.3	24
87	Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. Investigational New Drugs, 2014, 32, 340-346.	2.6	24
88	Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. European Journal of Cancer, 2011, 47, 997-1005.	2.8	23
89	Adenosine Triphosphate Quantification Correlates Poorly with Microbial Contamination of Duodenoscopes. Infection Control and Hospital Epidemiology, 2017, 38, 678-684.	1.8	23
90	Differential Outcomes in Codon 12/13 and Codon 61NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients withNRAS-Mutated Tumors. Clinical Cancer Research, 2021, 27, 2996-3004.	7.0	23

#	Article	IF	Citations
91	Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biology and Therapy, 2009, 8, 2004-2009.	3.4	22
92	A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research, 2012, 18, 5081-5089.	7.0	22
93	Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. JCO Precision Oncology, 2021, 5, 133-144.	3.0	22
94	National Cancer Institute Basket/Umbrella Clinical Trials. Cancer Journal (Sudbury, Mass), 2019, 25, 272-281.	2.0	21
95	Delivering on the promise. Current Opinion in Oncology, 2015, 27, 475-481.	2.4	20
96	Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. Journal of the National Cancer Institute, 2016, 108, djv437.	6.3	20
97	Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.. Journal of Clinical Oncology, 2018, 36, 100-100.	1.6	20
98	Improving attribution of adverse events in oncology clinical trials. Cancer Treatment Reviews, 2019, 76, 33-40.	7.7	19
99	Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute. Oncologist, 2021, 26, e1883-e1886.	3.7	19
100	GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials. Cancer Informatics, 2015, 14s2, CIN.S17282.	1.9	18
101	A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.. Journal of Clinical Oncology, 2015, 33, 5507-5507.	1.6	18
102	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clinical Cancer Research, 2017, 23, 4119-4126.	7.0	17
103	Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. Clinical Breast Cancer, 2018, 18, e135-e142.	2.4	17
104	A phase I study of chronically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt).. Journal of Clinical Oncology, 2012, 30, 3054-3054.	1.6	17
105	The Importance of Clinical Grading of Heart Failure and Other Cardiac Toxicities During Chemotherapy: Updating the Common Terminology Criteria for Clinical Trial Reporting. Heart Failure Clinics, 2011, 7, 373-384.	2.1	16
106	Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Journal of Neuro-Oncology, 2017, 132, 181-188.	2.9	16
107	Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers. Clinical Cancer Research, 2019, 25, 3084-3095.	7.0	16
108	NCI 8628: A randomized phase 2 study of zivâ€aflibercept and highâ€dose interleukin 2 or highâ€dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer, 2018, 124, 4332-4341.	4.1	15

#	Article	IF	Citations
109	The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. Neuro-Oncology Advances, 2020, 2, vdaa095.	0.7	15
110	PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components. OncoTargets and Therapy, 2022, Volume 15, 165-180.	2.0	15
111	Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition ofÂGamma-Secretase. Journal of Investigative Dermatology, 2018, 138, 979-981.	0.7	14
112	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. British Journal of Clinical Pharmacology, 2019, 85, 2499-2511.	2.4	14
113	Advances in the management of alveolar soft part sarcoma. Current Problems in Cancer, 2021, 45, 100775.	2.0	14
114	Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis. Cancer Research, 2016, 76, CT101-CT101.	0.9	14
115	Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.. Journal of Clinical Oncology, 2014, 32, 1021-1021.	1.6	14
116	A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs).. Journal of Clinical Oncology, 2016, 34, 8512-8512.	1.6	14
117	A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas. Oncologist, 2018, 23, 1269-e125.	3.7	13
118	Intravenous 5-fluoro-2â€²-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 85, 979-993.	2.3	13
119	Outcome of BRCA 1/2-mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).. Journal of Clinical Oncology, 2014, 32, 135-135.	1.6	13
120	Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 170-170.	1.6	13
121	A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients. Cancer Chemotherapy and Pharmacology, 2001, 48, 215-222.	2.3	12
122	Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas. Cancer Chemotherapy and Pharmacology, 2013, 72, 917-923.	2.3	12
123	Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 86, 815-827.	2.3	12
124	Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using ⁶⁸Ga-DOTATATE, FDG, ¹⁸F-FDOPA, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 13	2.2	12
125	Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology, 2020, 38, 3612-3612.	1.6	12
126	Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion. Cancer Chemotherapy and Pharmacology, 2001, 47, 117-125.	2.3	11

#	Article	IF	Citations
127	The root causes of pharmacodynamic assay failure. Seminars in Oncology, 2016, 43, 484-491.	2.2	11
128	Phase I study of veliparib in combination with gemcitabine. Cancer Chemotherapy and Pharmacology, 2017, 80, 631-643.	2.3	11
129	Cediranib phaseâ€I study in children with metastatic alveolar softâ€part sarcoma (ASPS). Pediatric Blood and Cancer, 2019, 66, e27987.	1.5	11
130	Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. Oncologist, 2020, 25, e1158-e1169.	3.7	11
131	A phaseÂI study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies.. Journal of Clinical Oncology, 2012, 30, 3049-3049.	1.6	11
132	Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Targeted Oncology, 2013, 8, 117-125.	3.6	10
133	Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations. Cancer Research, 2019, 79, CT138-CT138.	0.9	10
134	Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.. Journal of Clinical Oncology, 2019, 37, 3002-3002.	1.6	10
135	Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas. Clinical Cancer Research, 2022, 28, 279-288.	7.0	10
136	Assessment of Phospholipid Malabsorption by Quantification of Fecal Phospholipid. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, 85-91.	1.8	9
137	A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2010, 52, 122-128.	2.8	9
138	Population pharmacokinetics and exposureâ€“response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer Chemotherapy and Pharmacology, 2019, 83, 319-328.	2.3	9
139	A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecologic Oncology, 2020, 156, 13-22.	1.4	9
140	Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2015, 33, 520-520.	1.6	9
141	Phase I study of indenoisoquinolines LMP776 in adults with relapsed solid tumors and lymphomas.. Journal of Clinical Oncology, 2017, 35, 2558-2558.	1.6	9
142	Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.. Journal of Clinical Oncology, 2020, 38, 3506-3506.	1.6	9
143	Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precision Oncology, 2022, 6, e2100424.	3.0	9
144	Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials. Seminars in Oncology, 2016, 43, 446-452.	2.2	8

#	Article	IF	Citations
145	Impact of NCI-MATCH: a Nationwide Oncology Precision Medicine Trial. Expert Review of Precision Medicine and Drug Development, 2019, 4, 251-258.	0.7	8
146	The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. Human Vaccines and Immunotherapeutics, 2021, 17, 1935-1939.	3.3	8
147	Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations. , 2019, , .		8
148	Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma.. Journal of Clinical Oncology, 2012, 30, 5020-5020.	1.6	8
149	NCI mpact: National Cancer Institute molecular profiling-based assignment of cancer therapy.. Journal of Clinical Oncology, 2014, 32, TPS2642-TPS2642.	1.6	8
150	A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.. Journal of Clinical Oncology, 2020, 38, 639-639.	1.6	8
151	Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas. Oncotarget, 2020, 11, 3959-3971.	1.8	8
152	Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.. Journal of Clinical Oncology, 2019, 37, 3067-3067.	1.6	8
153	Feasibility of molecular profiling based assignment of cancer treatment (MPACT): A randomized NCI precision medicine study.. Journal of Clinical Oncology, 2016, 34, 2539-2539.	1.6	7
154	Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database.. Journal of Clinical Oncology, 2017, 35, 2534-2534.	1.6	7
155	Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial. JCO Precision Oncology, 2020, 4, 1207-1216.	3.0	6
156	Phase 1 study of Z-Endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors. Oncotarget, 2021, 12, 268-277.	1.8	6
157	Abstract CT325: Combination of the PARP inhibitor veliparib (ABT888) with irinotecan in patients with triple negative breast cancer: Preliminary activity and signature of response. Cancer Research, 2015, 75, CT325-CT325.	0.9	6
158	NCI-MATCH (Molecular Analysis for Therapy Choice) â€“ a national signal finding trial.. Journal of Clinical Oncology, 2016, 34, TPS2606-TPS2606.	1.6	6
159	A multiplex immunofluorescence assay to assess immune checkpoint inhibitor-targeted CD8 activation and tumor colocalization in FFPE tissues.. Journal of Clinical Oncology, 2019, 37, 2629-2629.	1.6	6
160	The use of research biopsies in oncology trials: challenges and controversies. Journal of Hospital Management and Health Policy, 2019, 3, 7-7.	0.4	5
161	A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.. Journal of Clinical Oncology, 2019, 37, 5523-5523.	1.6	5
162	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 721-735.	2.3	5

#	Article	IF	Citations
163	A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.. Journal of Clinical Oncology, 2021, 39, 3087-3087.	1.6	4
164	Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecologic Oncology, 2021, 161, 512-515.	1.4	4
165	Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib forCCND1, 2 or 3amplified tumors. , 2019, , .		4
166	A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia.. Journal of Clinical Oncology, 2015, 33, TPS5613-TPS5613.	1.6	4
167	Incorporating Patient-Reported Outcomes Into Early-Phase Trials. , 2018, , 193-208.		3
168	553P Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophgeal HER2-amplified tumours: Results of the NCI-MATCH trial (EAY131) subprotocol J. Annals of Oncology, 2020, 31, S479-S480.	1.2	3
169	Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies. Molecular Cancer Therapeutics, 2021, 20, 749-760.	4.1	3
170	Phase I trial of 5-aza-4â€™-thio-2â€™-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3088-3088.	1.6	3
171	Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. Investigational New Drugs, 2021, 39, 1577-1586.	2.6	3
172	Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors.. Journal of Clinical Oncology, 2014, 32, 2503-2503.	1.6	3
173	A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis.. Journal of Clinical Oncology, 2014, 32, 4139-4139.	1.6	3
174	Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.. Journal of Clinical Oncology, 2016, 34, 11028-11028.	1.6	3
175	Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 2619-2619.	1.6	3
176	Genomic profiling of three pathways through molecular profiling-based assignment of cancer therapy (NCI- MPACT). Annals of Oncology, 2019, 30, v164-v165.	1.2	2
177	Abstract CT138: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes. Cancer Research, 2021, 81, CT138-CT138.	0.9	2
178	Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemotherapy and Pharmacology, 1995, 36, 513-523.	2.3	2
179	Abstract B105: Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas. , 2019, , .		2
180	Abstract PR07: Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2019, , .		2

#	Article	IF	Citations
181	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias. Blood, 2015, 126, 1361-1361.	1.4	2
182	Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).. Journal of Clinical Oncology, 2015, 33, 358-358.	1.6	2
183	A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.. Journal of Clinical Oncology, 2016, 34, 2556-2556.	1.6	2
184	Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network.. Journal of Clinical Oncology, 2019, 37, 3016-3016.	1.6	2
185	A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. Cancer Chemotherapy and Pharmacology, 2022, 89, 49-58.	2.3	2
186	Final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.. Journal of Clinical Oncology, 2016, 34, 2584-2584.	1.6	2
187	Pazopanib to suppress MET signaling in patients with refractory advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2553-2553.	1.6	2
188	Abstract LBA003: Erdafitinib in patients with tumors harboring FGFR gene mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2. , 2021, , .		2
189	Phase I study of the PARP inhibitor ABT-888 (veliparib) and pegylated liposomal doxorubicin (PLD) in recurrent ovarian (ov) and breast (br) cancers. Gynecologic Oncology, 2012, 125, S22.	1.4	1
190	PARP Inhibition to Enhance Response to Chemotherapy. , 2019, , 231-257.		1
191	BRCA Mutation and PARP Inhibitors. , 2021, , 533-575.		1
192	Abstract 4643: Phase I pharmacokinetics and pharmacodynamics of a novel indenoisoquinoline topoisomerase 1 (TOP1) inhibitor, LMP400, administered on a daily x 5 schedule. Cancer Research, 2014, 74, 4643-4643.	0.9	1
193	Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations. , 2017, , .		1
194	Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).. Journal of Clinical Oncology, 2016, 34, TPS2596-TPS2596.	1.6	1
195	A phase I trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.. Journal of Clinical Oncology, 2017, 35, 2518-2518.	1.6	1
196	Suitability factors of core needle biopsies for pharmacodynamic (PD) studies.. Journal of Clinical Oncology, 2017, 35, 2540-2540.	1.6	1
197	Phase 1 study of onalespib, HSP90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS2617-TPS2617.	1.6	1
198	Development and analytical validation of a 523-gene clinical assay for cell-free DNA.. Journal of Clinical Oncology, 2019, 37, 3039-3039.	1.6	1

#	Article	IF	Citations
199	Role of adaptive randomization in developing novel therapies for patients with breast cancer. Translational Cancer Research, 2016, 5, S1119-S1122.	1.0	1
200	Using gamma-H2AX and H2AX quantitative ELISA for monitoring DNA damage induced by chemotherapeutic agents and irradiation exposure.. Journal of Clinical Oncology, 2015, 33, 2559-2559.	1.6	1
201	Abstract 3840: The National Cancer Instituteâ€™s patient-derived models repository (PDMR). , 2017, , .		1
202	Abstract 986: The National Cancer Institute's patient-derived models repository (PDMR). , 2018, , .		1
203	Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib). Cancer Research, 2019, 79, CT099-CT099.	0.9	1
204	Abstract LB-293: A Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed metastatic colorectal carcinoma. , 2019, , .		1
205	Abstract 4524: Comparison of PDX, PDC, and PDOrg models from the National Cancer Instituteâ€™s Patient-Derived Models Repository (PDMR). , 2019, , .		1
206	Abstract A079: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies. , 2019, , .		1
207	Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).. Journal of Clinical Oncology, 2020, 38, 3624-3624.	1.6	1
208	Abstract 5056: Quality control efforts in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository (NCI PDMR). , 2020, , .		1
209	Abstract P049: Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with advanced non-small cell lung cancer. , 2021, , .		1
210	N of 2 Responders With LMNA-NTRK1. Journal of the National Cancer Institute, 2016, 108, .	6.3	0
211	New Treatment Options for Ovarian Cancer. , 2019, , 533-540.		0
212	Abstract 3010: Single agent response comparisons in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository. , 2021, , .		0
213	Abstract CT115: Phase I trial of the triplet berzosertib (M6620, VX-970), veliparib and cisplatin (BVP) in patients with advanced solid tumors. , 2021, , .		0
214	Abstract 3012: Patient-derived models of rare cancers in the National Cancer Institute's patient-derived models repository. , 2021, , .		0
215	Abstract 3718: A Phase II Study of Sorafenib plus Cetuximab in colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR) and mutatedK-ras. , 2010, , .		0
216	Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias. Blood, 2010, 116, 3276-3276.	1.4	0

#	Article	IF	Citations
217	Abstract 1301: Investigation of a potential pharmacokinetic interaction between ABT-888 and topotecan in a phase I trial. , 2011, , .		0
218	Abstract 4682: Compensatory activation of alternative DNA repair pathways following exposure to the PARP Inhibitor ABT-888in vitroand in patients with solid malignancies. , 2012, , .		0
219	Abstract 5586: Phase I study of PARP inhibitor ABT-888 and carboplatin with novel imaging in metastatic breast cancer (MBC) (NCI-8609). , 2012, , .		0
220	Abstract LB-139: Phase I trial of veliparib or mitomycin (MMC) + veliparib in patients with sporadic solid tumors screened for somatic deficiency in the Fanconi Anemia (FA) pathway.. , 2013, , .		0
221	BRCA Mutation and PARP Inhibitors. , 2013, , 417-447.		0
222	NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanomaâ€"Efficacy and biomarker study.. Journal of Clinical Oncology, 2014, 32, TPS9120-TPS9120.	1.6	0
223	Abstract 4689: Pre-clinical investigation of the wee1 inhibitor MK-1775 using pharmacodynamic and mechanistic markers in diverse cancer modelsin vivo. , 2014, , .		0
224	Safety and Early Efficacy Analysis of a Novel Combination of the PARP Inhibitor Veliparib (ABT-888) Plus Bendamustine and Rituximab in Patients with Lymphoma. Blood, 2014, 124, 1739-1739.	1.4	0
225	Abstract CT316: A phase I trial of oral TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with relapsed solid tumors. , 2015, , .		0
226	Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma. Blood, 2015, 126, 2691-2691.	1.4	0
227	Abstract CT121: Demographics of clinical trial participants for new molecular entity (NME) oncology drugs and biologics approved by FDA CDER in 2015. , 2016, , .		0
228	Phase I trial of the triplet veliparib + VX-970 + cisplatin in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS2609-TPS2609.	1.6	0
229	Abstract 845: A clinically validated multiplex immunofluorescence assay for the quantitative assessment of changes in EMT phenotypes in FFPE tumor tissues in response to cancer therapeutics. , 2017, , .		0
230	Abstract 3827: NCI 8628 - A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma. , 2017, , .		0
231	Role of HSP90 Inhibitors in the Treatment of Cancer. Heat Shock Proteins, 2019, , 125-143.	0.2	0
232	Pregnancies in subjects on oncology clinical trials: Analysis from the Cancer Therapy Evaluation Program (CTEP) database.. Journal of Clinical Oncology, 2019, 37, e18239-e18239.	1.6	0
233	Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers. , 2019, , .		0
234	Abstract A071: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes. , 2019, , .		0

#	Article	IF	Citations
235	Abstract A050: Validation of Î²-catenin as a tumor segmentation marker for delineating tumor from stromal tissues in quantitative multiplex immunofluorescence analysis of formalin-fixed, paraffin-embedded biopsy specimens. , 2019, , .		0
236	Abstract A089: Adolescent and young adult (AYA) cohort of the NCI MATCH clinical trial (EAY131). , 2019, , .		0
237	Abstract C008: Tolerability and antitumor activity of paclitaxel is improved by the addition of nilotinib in patients with refractory solid tumors. , 2019, , .		0
238	Abstract B018: Restoration of p16INK4Aexpression in circulating tumor cells in patients with advanced solid tumors treated with deoxycytidine analogs and associated dynamic EMT phenotypic changes. , 2019, , .		0
239	Abstract CT061: Binimetinib in patients with tumors withNRASmutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A. , 2020, , .		0
240	Abstract 805: Intra-tumoral pharmacodynamics of selumetinib in serial biopsies from patients with neurofibroma. , 2020, , .		0
241	Abstract 802: Implementation of optimized research biopsy analyses for clinical pharmacodynamic (PD) studies. , 2020, , .		0
242	Abstract P222: Combinations of receptor tyrosine kinase inhibitors targeting the tumor and stromal cells of complex spheroids from the National Cancer Instituteâ€™s Patient-Derived Models Repository (PDMR; https://pdmr.cancer.gov/). , 2021, , .		0
243	Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib). , 2019, , .		0
244	Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containingBRCA1andBRCA2mutations. , 2019, , .		0
245	Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations. , 2019, , .		0
246	Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib forCCND1, 2 or 3amplified tumors. , 2019, , .		0
247	Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers. , 2019, , .		0
248	Abstract LB-293: A Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed metastatic colorectal carcinoma. , 2019, , .		0